Sanofi SA (NASDAQ:SNY) reported Wednesday new data from a Phase 2 study in relapsing multiple sclerosis. What Happened: The company’s CD40L antibody, frexalimab, demonstrated sustained reduction of disease activity. It also demonstrated favorable tolerability after nearly one year in participants with relapsing multiple sclerosis.  "These 48-week data showed that treatment with frexalimab resulted in further decreases in the number of lesions and a sustained reduction in disease activity. The preliminary clinical results are promising with a very low annual relapse rate," said Patrick Vermersch. Also Read: In Heart Burn Drug Zantac’s Litigation Saga, Sanofi ...